IMV Revenue and Competitors
Estimated Revenue & Valuation
- IMV's estimated annual revenue is currently $20M per year.
- IMV's estimated revenue per employee is $526,184
- IMV's total funding is $79.6M.
Employee Data
- IMV has 38 Employees.
- IMV grew their employee count by -54% last year.
IMV's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Accounting Officer (CAO) | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | SVP, Human Resources and Internal Communications | Reveal Email/Phone |
4 | SVP, Investor Relations and Corporate Strategy | Reveal Email/Phone |
5 | VP, Regulatory Affairs | Reveal Email/Phone |
6 | VP, Translational Research | Reveal Email/Phone |
7 | VP, Project Management and Operations | Reveal Email/Phone |
8 | Chief Scientific Officer, IMV, Inc. | Reveal Email/Phone |
9 | Director, Compliance Management | Reveal Email/Phone |
10 | Snr. Director, Formulation Development | Reveal Email/Phone |
IMV Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is IMV?
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company?s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the reprogramming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently conducting three Phase 2 studies with Incyte and Merck assessing DPX-Survivac as a combination therapy in ovarian cancer and diffuse large B-cell lymphoma. For more information, please connect at: www.imv-inc.com
keywords:N/A
$79.6M
Total Funding
38
Number of Employees
$20M
Revenue (est)
-54%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Dartmouth
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.3M | 40 | 5% | N/A |
#2 | $10.8M | 41 | 3% | N/A |
#3 | $20M | 42 | -57% | $79.6M |
#4 | $9.6M | 42 | -2% | N/A |
#5 | $8.8M | 44 | -4% | N/A |